15-66481834-C-T
Variant summary
Our verdict is Benign. The variant received -8 ACMG points: 0P and 8B. BA1
This summary comes from the ClinGen Evidence Repository: The filtering allele frequency of the c.648C>T (p.Ile216=) variant in the MAP2K1 gene is 0.274% (38/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581) LINK:https://erepo.genome.network/evrepo/ui/classification/CA134607/MONDO:0021060/004
Frequency
Consequence
NM_002755.4 synonymous
Scores
Clinical Significance
Conservation
Publications
- cardiofaciocutaneous syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- cardiofaciocutaneous syndrome 3Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: G2P, Ambry Genetics, Labcorp Genetics (formerly Invitae), PanelApp Australia, Genomics England PanelApp
- Noonan syndrome with multiple lentiginesInheritance: AD Classification: STRONG, LIMITED Submitted by: Genomics England PanelApp, ClinGen
- Noonan syndromeInheritance: AD Classification: LIMITED Submitted by: ClinGen
- Costello syndromeInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -8 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MAP2K1 | NM_002755.4 | c.648C>T | p.Ile216Ile | synonymous_variant | Exon 6 of 11 | ENST00000307102.10 | NP_002746.1 | |
| MAP2K1 | NM_001411065.1 | c.504C>T | p.Ile168Ile | synonymous_variant | Exon 5 of 10 | NP_001397994.1 | ||
| MAP2K1 | XM_011521783.4 | c.582C>T | p.Ile194Ile | synonymous_variant | Exon 6 of 11 | XP_011520085.1 | ||
| MAP2K1 | XM_017022411.3 | c.570C>T | p.Ile190Ile | synonymous_variant | Exon 5 of 10 | XP_016877900.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MAP2K1 | ENST00000307102.10 | c.648C>T | p.Ile216Ile | synonymous_variant | Exon 6 of 11 | 1 | NM_002755.4 | ENSP00000302486.5 |
Frequencies
GnomAD3 genomes AF: 0.00112 AC: 170AN: 152178Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000302 AC: 76AN: 251474 AF XY: 0.000221 show subpopulations
GnomAD4 exome AF: 0.000113 AC: 165AN: 1461724Hom.: 0 Cov.: 32 AF XY: 0.0000949 AC XY: 69AN XY: 727174 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00112 AC: 170AN: 152296Hom.: 0 Cov.: 32 AF XY: 0.00106 AC XY: 79AN XY: 74470 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
RASopathy Benign:2
The filtering allele frequency of the c.648C>T (p.Ile216=) variant in the MAP2K1 gene is 0.274% (38/10402) of African chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581) -
- -
not specified Benign:1
Ile216Ile in exon 6 of MAP2K1: This variant is not expected to have clinical sig nificance because it does not alter an amino acid residue and it is not located within the splice consensus sequence. -
MAP2K1-related disorder Benign:1
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
not provided Benign:1
- -
Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Noonan syndrome and Noonan-related syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at